Cheng Cen

Title: Cheng Cen: Innovator in Cancer Treatment

Introduction

Cheng Cen is a notable inventor based in Shanghai, China. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the creation of novel compounds that target specific mutations associated with various cancers.

Latest Patents

Cheng Cen holds a patent for "Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers." This patent discloses a nitrogen-containing heterocyclic derivative regulator, along with its preparation method and application. The compound, represented by a general formula, is utilized as a KRAS G12C mutation inhibitor in the treatment of diseases such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer, and colon cancer.

Career Highlights

Throughout his career, Cheng Cen has worked with prominent companies in the pharmaceutical industry. He has been associated with Shanghai Hansoh Biomedical Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Cheng Cen has collaborated with several professionals in his field, including Shiqiang Liu and Rudi Bao. These partnerships have enhanced his research efforts and have led to advancements in cancer treatment methodologies.

Conclusion

Cheng Cen is a distinguished inventor whose work in developing KRAS G12C inhibitors represents a significant advancement in cancer therapy. His contributions to the pharmaceutical industry continue to impact the treatment of various cancers, showcasing the importance of innovation in medical research.